Enovis (NYSE:ENOV) Stock Price Down 6.9% – Here’s Why

Enovis Corporation (NYSE:ENOV) traded down 6.9% during mid-day trading on Wednesday . The stock traded as low as $22.97 and last traded at $22.6160. 324,629 shares traded hands during mid-day trading, a decline of 69% from the average session volume of 1,042,034 shares. The stock had previously closed at $24.28.

Analyst Ratings Changes

Several research firms have recently weighed in on ENOV. William Blair began coverage on shares of Enovis in a research report on Friday, April 17th. They set an “outperform” rating on the stock. Zacks Research upgraded shares of Enovis from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 4th. Wells Fargo & Company lowered their price objective on shares of Enovis from $42.00 to $40.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Evercore restated an “outperform” rating and set a $36.00 price objective on shares of Enovis in a research report on Friday, May 8th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Enovis in a research report on Friday, April 10th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Enovis has an average rating of “Moderate Buy” and a consensus target price of $44.50.

Enovis Stock Performance

The company has a current ratio of 2.04, a quick ratio of 1.05 and a debt-to-equity ratio of 0.87. The company’s fifty day moving average is $24.05 and its 200 day moving average is $25.18. The company has a market cap of $1.33 billion, a P/E ratio of -1.16 and a beta of 1.41.

Enovis (NYSE:ENOV) last released its earnings results on Thursday, May 7th. The company reported $0.89 EPS for the quarter, beating the consensus estimate of $0.82 by $0.07. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The company had revenue of $589.15 million for the quarter, compared to analyst estimates of $572.02 million. During the same quarter last year, the firm earned $0.81 EPS. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities analysts predict that Enovis Corporation will post 3.65 earnings per share for the current fiscal year.

Insider Activity at Enovis

In other Enovis news, insider Oliver Engert bought 1,000 shares of Enovis stock in a transaction that occurred on Friday, February 27th. The shares were bought at an average price of $25.50 per share, with a total value of $25,500.00. Following the acquisition, the insider owned 43,640 shares in the company, valued at approximately $1,112,820. This trade represents a 2.35% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders have acquired 5,000 shares of company stock worth $121,983. 2.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Enovis

Several institutional investors and hedge funds have recently made changes to their positions in the business. Rubric Capital Management LP bought a new stake in Enovis in the 3rd quarter worth $83,435,000. Paradigm Capital Management Inc. NY grew its holdings in Enovis by 70.2% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock worth $40,420,000 after acquiring an additional 732,917 shares during the last quarter. AQR Capital Management LLC grew its holdings in Enovis by 682.6% in the 2nd quarter. AQR Capital Management LLC now owns 498,317 shares of the company’s stock worth $15,627,000 after acquiring an additional 434,646 shares during the last quarter. Front Street Capital Management Inc. grew its holdings in Enovis by 106.1% in the 1st quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock worth $16,973,000 after acquiring an additional 384,124 shares during the last quarter. Finally, Quantinno Capital Management LP grew its holdings in Enovis by 130.8% in the 1st quarter. Quantinno Capital Management LP now owns 604,500 shares of the company’s stock worth $13,752,000 after acquiring an additional 342,556 shares during the last quarter. Institutional investors own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.